LHDX
Lucira Health, Inc. [LHDX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
LHDX Stock Summary
In the News
LHDX Financial details
Company Rating
Neutral
Market Cap
18.36M
Income
-143M
Revenue
212.13M
Book val./share
1.51
Cash/share
0.99
Dividend
-
Dividend %
-
Employees
221
Optionable
No
Shortable
Yes
Earnings
10 May 2023
P/E
-0.13
Forward P/E
-
PEG
-0.01
P/S
0.12
P/B
0.3
P/C
-
P/FCF
-0.2
Quick Ratio
0.71
Current Ratio
1.46
Debt / Equity
0.79
LT Debt / Equity
0.75
-
-
EPS (TTM)
-3.57
EPS next Y
-
EPS next Q
-
EPS this Y
78.85%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
31.53%
EPS Q/Q
483.33%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
15.8%
Inst Trans
0.68%
ROA
-72%
ROE
-90%
ROC
-1.26%
Gross Margin
-34%
Oper. Margin
-89%
Profit Margin
-90%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.108-4.35
52W High
-
52W Low
-
RSI
-
Rel Volume
1.69
Avg Volume
21.45M
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
3.75954
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
LHDX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2021-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0.01 | 2.68 | |
| Net income per share | -0.85 | -0.56 | -1.04 | -1.86 | |
| Operating cash flow per share | -0.82 | -0.46 | -0.91 | -2.9 | |
| Free cash flow per share | -0.84 | -0.46 | -1.43 | -3.34 | |
| Cash per share | 0.01 | 0.27 | 1.62 | 3.05 | |
| Book value per share | -2.22 | -1.67 | -1.74 | 5.43 | |
| Tangible book value per share | -2.22 | -1.67 | -1.74 | 5.43 | |
| Share holders equity per share | -2.22 | -1.67 | -1.74 | 5.43 | |
| Interest debt per share | 0.56 | 0.08 | 0.71 | 0.08 | |
| Market cap | 197.66M | 384.73M | 895.96M | 299.36M | |
| Enterprise value | 201.83M | 381.74M | 863.26M | 196.2M | |
| P/E ratio | -29.39 | -44.96 | -23.96 | -4.62 | |
| Price to sales ratio | 0 | 0 | 3.33K | 3.22 | |
| POCF ratio | -30.57 | -54.48 | -27.55 | -2.97 | |
| PFCF ratio | -29.9 | -53.91 | -17.45 | -2.57 | |
| P/B Ratio | -11.25 | -14.99 | -14.38 | 1.59 | |
| PTB ratio | -11.25 | -14.99 | -14.38 | 1.59 | |
| EV to sales | 0 | 0 | 3.21K | 2.11 | |
| Enterprise value over EBITDA | -34.13 | -51.45 | -29.26 | -3.22 | |
| EV to operating cash flow | -31.22 | -54.06 | -26.54 | -1.94 | |
| EV to free cash flow | -30.53 | -53.49 | -16.82 | -1.69 | |
| Earnings yield | -0.03 | -0.02 | -0.04 | -0.22 | |
| Free cash flow yield | -0.03 | -0.02 | -0.06 | -0.39 | |
| Debt to equity | -0.24 | -0.04 | -0.41 | 0.01 | |
| Debt to assets | 1 | 0.15 | 0.28 | 0.01 | |
| Net debt to EBITDA | -0.7 | 0.4 | 1.11 | 1.7 | |
| Current ratio | 0.49 | 3.83 | 7.93 | 4.1 | |
| Interest coverage | -51.66 | -153.98 | -602.36 | -21.51K | |
| Income quality | 0.99 | 0.83 | 0.87 | 1.56 | |
| Dividend Yield | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 91.52 | 0.43 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.02 | 0.01 | 0.58 | 0.15 | |
| Capex to revenue | 0 | 0 | -69.93 | -0.17 | |
| Capex to depreciation | -0.59 | -0.27 | -67.19 | -4.19 | |
| Stock based compensation to revenue | 0 | 0 | 1.62 | 0.09 | |
| Graham number | 6.52 | 4.56 | 6.38 | 15.09 | |
| ROIC | 0.82 | 0.6 | 0.89 | -0.33 | |
| Return on tangible assets | -1.57 | -1.12 | -0.4 | -0.27 | |
| Graham Net | -2.51 | -1.81 | -2.62 | 3.06 | |
| Working capital | -2.81M | 4.53M | 61.37M | 155.95M | |
| Tangible asset value | -17.57M | -25.67M | -62.31M | 188.8M | |
| Net current asset value | -19.15M | -27.14M | -84.78M | 154.73M | |
| Invested capital | -0.24 | -0.04 | -0.41 | 0.01 | |
| Average receivables | 0 | 2.13M | 1.13M | 17.95M | |
| Average payables | 0 | 748.5K | 2.28M | 11.68M | |
| Average inventory | 0 | 0 | 2.43M | 27.82M | |
| Days sales outstanding | 0 | 0 | 645.87 | 138.98 | |
| Days payables outstanding | 0 | 0 | 748.62 | 85.36 | |
| Days of inventory on hand | 0 | 0 | 914.85 | 223.75 | |
| Receivables turnover | 0 | 0 | 0.57 | 2.63 | |
| Payables turnover | 0 | 0 | 0.49 | 4.28 | |
| Inventory turnover | 0 | 0 | 0.4 | 1.63 | |
| ROE | 0.38 | 0.33 | 0.6 | -0.34 | |
| Capex per share | -0.02 | 0 | -0.52 | -0.44 |
Quarterly Fundamentals Overview
Last date of statement is 2022-09-30 for Q3
| Metric | History | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0.39 | 1.57 | 2.16 | 0.65 | 0.86 | |
| Net income per share | -0.71 | -0.19 | 0.31 | -0.54 | -3.15 | |
| Operating cash flow per share | -1.12 | -0.26 | -0.13 | -0.97 | -0.7 | |
| Free cash flow per share | -1.16 | -0.38 | -0.32 | -1.12 | -0.88 | |
| Cash per share | 3.03 | 2.72 | 2.88 | 1.88 | 0.99 | |
| Book value per share | 5.02 | 4.84 | 4.89 | 4.63 | 1.51 | |
| Tangible book value per share | 5.02 | 4.84 | 4.89 | 4.63 | 1.51 | |
| Share holders equity per share | 5.02 | 4.84 | 4.89 | 4.63 | 1.51 | |
| Interest debt per share | 0.07 | 0.07 | 0.76 | 1.23 | 1.22 | |
| Market cap | 293.87M | 336.05M | 149.34M | 74.27M | 42.63M | |
| Enterprise value | 179.38M | 232.89M | 59.98M | 47.53M | 50.95M | |
| P/E ratio | -2.67 | -11.14 | 2.85 | -0.86 | -0.08 | |
| Price to sales ratio | 19.62 | 5.5 | 1.65 | 2.84 | 1.24 | |
| POCF ratio | -6.8 | -33.49 | -28.17 | -1.92 | -1.51 | |
| PFCF ratio | -6.53 | -22.94 | -11.12 | -1.66 | -1.2 | |
| P/B Ratio | 1.51 | 1.78 | 0.73 | 0.4 | 0.7 | |
| PTB ratio | 1.51 | 1.78 | 0.73 | 0.4 | 0.7 | |
| EV to sales | 11.98 | 3.81 | 0.66 | 1.82 | 1.48 | |
| Enterprise value over EBITDA | -6.84 | -35.52 | 4.32 | -2.45 | -0.41 | |
| EV to operating cash flow | -4.15 | -23.21 | -11.31 | -1.23 | -1.8 | |
| EV to free cash flow | -3.98 | -15.9 | -4.46 | -1.06 | -1.44 | |
| Earnings yield | -0.09 | -0.02 | 0.09 | -0.29 | -2.98 | |
| Free cash flow yield | -0.15 | -0.04 | -0.09 | -0.6 | -0.83 | |
| Debt to equity | 0.01 | 0.01 | 0.15 | 0.26 | 0.79 | |
| Debt to assets | 0.01 | 0.01 | 0.1 | 0.17 | 0.25 | |
| Net debt to EBITDA | 4.37 | 15.73 | -6.44 | 1.38 | -0.07 | |
| Current ratio | 7.03 | 4.1 | 3.72 | 3.81 | 1.46 | |
| Interest coverage | -5.52K | 1.3K | 25.72 | -25.89 | -133.08 | |
| Income quality | 1.57 | 1.28 | -0.41 | 1.79 | 0.22 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0.96 | 0.15 | 0.13 | 0.41 | 0.27 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.04 | 0.46 | 1.53 | 0.16 | 0.25 | |
| Capex to revenue | -0.12 | -0.08 | -0.09 | -0.23 | -0.21 | |
| Capex to depreciation | -1.41 | -3.05 | -5.09 | -3.64 | -4.12 | |
| Stock based compensation to revenue | 0.34 | 0.03 | 0.02 | 0.06 | 0.07 | |
| Graham number | 8.96 | 4.59 | 5.87 | 7.52 | 10.37 | |
| ROIC | -0.14 | -0.04 | 0.06 | -0.08 | -0.99 | |
| Return on tangible assets | -0.12 | -0.03 | 0.04 | -0.07 | -0.67 | |
| Graham Net | 3.08 | 2.73 | 2.29 | 1.07 | -1.15 | |
| Working capital | 165.43M | 155.95M | 190.1M | 162.6M | 37.95M | |
| Tangible asset value | 193.99M | 188.8M | 204.63M | 185.07M | 60.89M | |
| Net current asset value | 164.06M | 154.73M | 160.36M | 116.56M | -7.83M | |
| Invested capital | 0.01 | 0.01 | 0.15 | 0.26 | 0.79 | |
| Average receivables | 7.76M | 23.73M | 43.54M | 33.81M | 17.59M | |
| Average payables | 8.56M | 14.91M | 21.25M | 23.86M | 24.88M | |
| Average inventory | 39.57M | 46.87M | 61.84M | 96.24M | 87.6M | |
| Days sales outstanding | 72.29 | 52.17 | 51.37 | 54.97 | 50.29 | |
| Days payables outstanding | 57.16 | 35.95 | 41.19 | 121.88 | 16.91 | |
| Days of inventory on hand | 234.93 | 94.23 | 129.78 | 592.81 | 37.38 | |
| Receivables turnover | 1.24 | 1.73 | 1.75 | 1.64 | 1.79 | |
| Payables turnover | 1.57 | 2.5 | 2.19 | 0.74 | 5.32 | |
| Inventory turnover | 0.38 | 0.96 | 0.69 | 0.15 | 2.41 | |
| ROE | -0.14 | -0.04 | 0.06 | -0.12 | -2.08 | |
| Capex per share | -0.05 | -0.12 | -0.19 | -0.15 | -0.18 |
LHDX Frequently Asked Questions
What is Lucira Health, Inc. stock symbol ?
Lucira Health, Inc. is a US stock , located in Emeryville of Ca and trading under the symbol LHDX
What is Lucira Health, Inc. stock quote today ?
Lucira Health, Inc. stock price is $- today.
Is Lucira Health, Inc. stock public?
Yes, Lucira Health, Inc. is a publicly traded company.
Company Profile
- Volume Average 21.45M
- Market Capitalization 18.36M
- Employee 221
- CEO Mr. Erik T. Engelson
- Headquarters EmeryVille,CA,US
- IPO Date 2021-02-04
-
Website
https://www.lucirahealth.com 
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
